Regeneron Expands Ophthalmology Portfolio with Acquisition of UK-Based Biotech Oxular
Acquisition:
Regeneron has acquired Oxular, a UK-based clinical-stage biotech company specializing in ocular delivery technology for retinal disorders1.
Technology:
Oxular's proprietary technology includes Oxulumis, a semi-automated ocular administration device that delivers therapeutics to the suprachoroidal space, and Oxuspheres, biodegradable drug-containing polymer systems for sustained drug release24.
Lead Candidate:
Oxular's lead candidate, OXU-001, is a dexamethasone formulation in Oxuspheres, designed for the treatment of diabetic macular edema (DME). It is currently in a phase 2 trial, OXEYE, evaluating its efficacy over 52 weeks1.
Benefits:
Oxular's technology offers minimally invasive procedures, targeted drug delivery, and sustained treatment effects up to 12 months, addressing significant unmet needs in retinal disease treatment24.
Regeneron's Expansion:
The acquisition enhances Regeneron's ophthalmology portfolio, leveraging Oxular's innovative delivery technologies to maximize treatment efficacy and patient outcomes1.
Sources:
1. https://eyewire.news/news/regeneron-acquires-uk-based-biotech-oxular